Table 1.
Comparison between the three groups of participants before and after the tDCS treatment on the outcome measures.
| Variable | 5-days | 10-days | Sham | ANOVA | |||||
|---|---|---|---|---|---|---|---|---|---|
| Before | After | Before | Aafter | Before | After | Groups (5-days vs 10-days vs sham) | Times (before vs after treatment) | Interaction between groups and times | |
| Pain | 7.00 (1.73) | 5.05 (2.49) | 5.72 (1.56) | 5.22 (3.35) | 7.09 (1.61) | 4.82 (3.34) |
p = 0.792 η2 = 0.017 |
p = 0.008 η2 = 0.223 |
p = 0.417 η2 = 0.061 |
| Frontal alpha 2 | 1.07 (3.30) | − 0.24* (3.51) | 1.67 (2.41) | 1.80 (3.07) | 1.95 (2.79) | 2.92 (3.62) |
p = 0.297 η2 = 0.083 |
p = 0.854 η2 = 0.001 |
p = 0.040* η2 = 0.261 |
| Parietal alpha 2 | 3.77 (3.14) | 2.00* (3.63) | 5.31 (2.79) | 5.76 (4.07) | 2.82 (4.74) | 4.19 (5.10) |
p = 0.302 η2 = 0.082 |
p = 0.964 η2 = 0.001 |
p = 0.014* η2 = 0.261 |
| Occipital alpha 2 | 6.15 (2.99) | 4.35 (3.31) | 5.80 (3.57) | 5.99 (4.27) | 6.20 (5.23) | 7.20 (4.86) |
p = 0.680 η2 = 0.027 |
p = 0.716 η2 = 0.005 |
p = 0.104 η2 = 0.149 |
Values are presented as a function of means and standard deviations. For ANOVAs, p and η2 values are presented for the main factors (times and groups) and for the interaction between them. *Post hoc analyzes indicated a decrease in spectral power in frontal and parietal regions after the application of the 5-days tDCS protocol. Level of significance considered was of p < 0.05. SD Standard deviation; η2: Partial eta-squared as a measure of size effect.